Democratic-controlled congressional committees and left-leaning think tanks are significantly more likely than their Republican counterparts to reference research papers, a study suggests.

The FDA has accepted for priority review the resubmitted BLA for tabelecleucel to treat patients 2 years of age and older with EBV+ PTLD who have received at least 1 prior therapy.

A survey has revealed the top concerns people have when a loved one is diagnosed with cancer.

Hospital officials are warning that changes in President Donald Trump’s budget and tax bill put them on an unsustainable track that could lead to closures or loss of services in rural communities.

ASCO has updated its guidelines for the treatment of patients with stage IV NSCLC with and without driver alterations.

The FDA has decided not to approve glofitamab plus gemcitabine and oxaliplatin to treat certain patients with relapsed/refractory DLBCL.

Researchers recommended that regulators consider mandating head-to-head trials comparing next-in-class and against existing in-class agents when possible.

The FDA has approved once-monthly dosing of Elrexfio (elranatamab-bcmm) for certain patients with relapsed or refractory multiple myeloma.

Perioperative treatment with nivolumab and relatlimab provided long-term benefits in adults with stage III-IV, resectable melanoma.

Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.

As legal battles over the federal funding freeze and indirect cost payments from NIH play out in court, cancer research is being disrupted.

The Trump Administration’s censorship extends beyond federal websites and datasets to include research to be published in academic journals.